Table 4.
Baseline predictive factors of radiographic outcome at 10 years (univariate analysis)
| Baseline variables | Total Sharp score at 10 years | Radiographic progression | ||
| p | OR (95% CI) | p | OR (95% CI) | |
| Total Sharp score | < 0.0001 | 8.66 (3.72–20.15) | 0.003 | 3.72 (1.51–9.15) |
| Erosion score | < 0.0001 | 6.00 (2.68–13.39) | < 0.0001 | 8.47 (2.98–24.05) |
| Joint narrowing score | < 0.0001 | 4.71 (2.14–10.34) | 0.007 | 3.18 (1.33–7.62) |
| ACPA | 0.002 | 3.91 (1.59–9.61) | < 0.0001 | 10.88 (4.03–29.3) |
| Anti-CCP antibodies | 0.005 | 3.37 (1.40–8.11) | < 0.0001 | 8.62 (2.97–25.00) |
| IgA RF positivity | 0.01 | 3.19 (1.28–7.91) | 0.0001 | 5.89 (2.27–15.28) |
| ESR | 0.01 | 2.55 (1.21–5.39) | 0.34 | 1.47 (0.66–3.26) |
| IgA RF level | 0.02 | 2.40 (1.10–5.21) | 0.004 | 3.86 (1.46–10.17) |
| MMP3 level | 0.03 | 2.60 (1.07–6.30) | 0.003 | 5.00 (1.61–15.50) |
| Anti-perinuclear antibodies | 0.03 | 2.28 (1.05–4.93) | 0.0002 | 6.11 (2.22–16.77) |
| Swollen joint count | 0.05 | 0.48 (0.23–1.00) | 0.88 | 1.05 (0.47–2.33) |
| Morning stiffness | 0.08 | 2.10 (0.90–4.87) | 0.31 | 1.65 (0.61–4.42) |
| HLA-DRB1*01 | 0.08 | 0.49 (0.22–1.10) | 0.07 | 0.47 (0.20–1.08) |
| Tender joint count | 0.08 | 0.48 (0.21–1.10) | 0.13 | 0.48 (0.18–1.26) |
| IgM RF positivity | 0.10 | 1.95 (0.87–4.39) | 0.001 | 4.08 (1.63–10.20) |
| CRP | 0.19 | 1.63 (0.77–3.42) | 0.49 | 1.32 (0.58–2.99) |
| DAS | 0.26 | 1.52 (0.73–3.16) | 0.44 | 1.36 (0.61–3.05) |
| Anti-keratin antibodies | 0.32 | 1.46 (0.68–3.12) | 0.02 | 2.76 (1.09–7.00) |
| Age | 0.34 | 1.42 (0.67–3.00) | 0.007 | 3.28 (1.35–7.98) |
| Sex | 0.40 | 0.67 (0.27–1.69) | 0.14 | 0.42 (0.13–1.36) |
| Pain on VAS | 0.45 | 1.36 (0.60–3.07) | 0.44 | 0.69 (0.27–1.77) |
| YKL 40 | 0.56 | 1.69 (0.27–10.59) | 0.36 | 2.30 (0.36–14.66) |
| Anti-nuclear antibodies | 0.64 | 0.81 (0.34–1.93) | 0.79 | 1.13 (0.42–3.01) |
| Extra-articular signs | 0.68 | 1.29 (0.37–4.50) | 0.84 | 1.15 (0.28–4.63) |
| IgM RF level | 0.76 | 1.12 (0.52–2.39) | 0.01 | 3.05 (1.19–7.79) |
| Ritchie score | 0.85 | 1.06 (0.51–2.21) | 0.86 | 1.07 (0.48–2.38) |
| Anti-HSP90 antibodies | 0.92 | 0.95 (0.37–2.43) | 0.21 | 0.53 (0.19–1.44) |
| HAQ score | 0.95 | 0.97 (0.43–2.19) | 0.60 | 0.77 (0.30–2.00) |
ACPA, anti-citrullinated protein antibody; CCP, cyclic citrullinated peptide; CI, confidence interval; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HLA, human leucocyte antigen; HSP90, heat shock protein 90; MMP3, matrix metalloproteinase 3; OR, odds ratio; RF, rheumatoid factor; VAS, visual analogue score.